Building on this, Mason and colleagues (81) developed DXS31-164, a HER2/neu-targeted vaccine that significantly reduced pulmonary metastatic burden and prolonged lifespan in canine osteosarcoma models, indicating potential for translation to human HER2-positive osteosarcoma. The gene discussed is ERBB2; the disease is osteosarcoma.